Land: Irland
Sprog: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Tilmicosin
Huvepharma NV
QJ01FA91
Tilmicosin
250 milligram(s)/millilitre
Oral solution
POM: Prescription Only Medicine as defined in relevant national legislation
Cattle, Chickens, Pigs, Turkeys
tilmicosin
Antibacterial
Authorised
2008-10-24
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Tilmovet 250 mg/ml Concentrate for Oral Solution for pigs, chickens, turkeys and cattle (calves) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance Tilmicosin: 250 mg per ml. Excipients For the full list of excipients: see section 6.1 3 PHARMACEUTICAL FORM Concentrate for oral solution Clear yellow to amber solution 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Chickens (broilers and pullets), turkeys, pigs and cattle (calves). 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Pigs: For the treatment and prevention of respiratory infections associated with_ Mycoplasma hyopneumoniae_, _Pasteurella multocida and Actinobacillus pleuropneumoniae_ when the disease has been diagnosed at the herd level. Chickens: For the treatment and prevention of respiratory infections in poultry flocks associated with_ Mycoplasma gallisepticum_ _and Mycoplasma synoviae_ when the disease has been diagnosed at the herd level. Turkeys: For the treatment and prevention of respiratory infections in turkey flocks associated with_ Mycoplasma_ _gallisepticum_ and_ Mycoplasma synoviae_ when the disease has been diagnosed at the herd level. Calves: For the treatment and prevention of respiratory infections associated with_ Mannheimia haemolytica_,_ P._ _multocida, Mycoplasma bovis and M.dispar_ when the disease has been diagnosed at the herd level. 4.3 CONTRAINDICATIONS Do not use in case of hypersensitivity to the active substance or in cases of known resistance to tilmicosin. Do not use in horses. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Tilmicosin should not be administered by injection to pigs. The product contains disodium edetate.The uptake of medicated water can be altered as a consequence of illness. If the uptake is insufficient alternative treatment may be required. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Læs hele dokumentet